

08-13-2001

2 \$

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002)

RECC TF



101809567

U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Tab settings

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Dendreon Corporation (8-707) 3005 First Avenue Seattle, WA 98121

- Individual(s) Association General Partnership Limited Partnership Corporation-State Other

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment Merger Security Agreement Change of Name Other

Execution Date:

2. Name and address of receiving party(ies)

Transamerica Business Credit Internacorporation

Street Address: 76 Batterson Park Rd. City: Farmington State: CT Zip: 06032

- Individual(s) citizenship Association General Partnership Limited Partnership Corporation-State Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment) Additional name(s) & address(es) attached? Yes No

4. Application number(s) or registration number(s):

A. Trademark Application No. (s) 75/283,623

B. Trademark Registration No. (s) 2,188,041

Additional number(s) attached Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Brad Davis Internal Address: Reed fax

Street Address: 2001 Jefferson Davis Hwy suite 1207

City: Arlington State: VA Zip: 22202

6. Total number of applications and registrations involved: 10

7. Total fee (37 CFR 3.41): \$ 265

- Enclosed Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Moira Bessette-Martin Signature

Aug 3, 2001 Date

Total number of pages including cover sheet, attachments, and document: 24

Mail documents to be recorded with required cover sheet information to: Commissioner of Patent & Trademarks, Box Assignments Washington, D.C. 20231

08/10/2001 TDIAZ1 00000132 75283623

01 FC:481 02 FC:482

40.00 DP 225.00 DP

TRADEMARK REEL: 002345 FRAME: 0303



Continuation of Item 4:

Trademark Application Nos. (continued)

76/165,904

75/282,526

76/028,099

75/927,065

76/009,430

75/927,050

75/927,064

75/906,694



SUPPLEMENT ONE

TO

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This SUPPLEMENT ONE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement"), dated as of June 6, 2001, is entered into between **DENDREON CORPORATION**, a Delaware corporation ("Grantor"), which has a mailing address at 3005 First Avenue, Seattle, Washington 98121, and **TRANSAMERICA BUSINESS CREDIT CORPORATION**, a Delaware corporation, ("TBCC") having its principal office at 9399 West Higgins Road, Suite 600, Rosemont, Illinois 60018 and having an office at 15260 Ventura Blvd., Suite 1240, Sherman Oaks, California 91403. (Capitalized terms used herein shall have the meanings assigned to such terms in the Security Agreement and Master Lease unless otherwise defined herein.)

RECITALS

A. Grantor and TBCC previously entered into an Intellectual Property Security Agreement dated as of August 3, 1999 (the "Original Agreement"), which was recorded in the U.S. Patent and Trademark Office with respect to the trademarks and patents identified therein;

B. Grantor and TBCC, previously entered into that certain Loan and Security Agreement dated July 30, 1999, Security Agreement dated June 6, 2001 (collectively the "Security Agreement") and Master Lease Agreements dated December 11, 1997, as amended, and June 6, 2001 ("Master Lease") other instruments, documents and agreements contemplated thereby or related thereto (collectively, together with the Security Agreement, the "Loan and Lease Documents"); and

C. Grantor is the owner of certain additional intellectual property, identified below, in which Grantor is granting a security interest to TBCC.

NOW THEREFORE, in consideration of the mutual promises, covenants, conditions, representations, and warranties hereinafter set forth and for other good and valuable consideration, the parties hereto mutually agree as follows:

1. DEFINITIONS AND CONSTRUCTION.

1.1 Definitions. The following terms, as used in this Agreement, have the following meanings:

"Code" means the California Uniform Commercial Code, as amended and supplemented from time to time, and any successor statute.

"Intellectual Property Collateral" means all of the following, whether now owned or hereafter acquired:

(i) Each of the trademarks and rights and interest which are capable of being protected as trademarks (including trademarks, service marks, designs, logos, indicia, tradenames, corporate names, company names, business names, fictitious business names, trade styles, and other source or business identifiers, and applications pertaining thereto), which are presently, or in the future may be, owned, created, acquired, or used (whether pursuant to a license or otherwise) by Grantor, in whole or in

part, and all trademark rights with respect thereto throughout the world, including all proceeds thereof (including license royalties and proceeds of infringement suits), and rights to renew and extend such trademarks and trademark rights;

(ii) Each of the patents and patent applications which are presently, or in the future may be, owned, issued, acquired, or used (whether pursuant to a license or otherwise) by Grantor, in whole or in part, and all patent rights with respect thereto throughout the world, including all proceeds thereof (including license royalties and proceeds of infringement suits), foreign filing rights, and rights to extend such patents and patent rights;

(iii) All of Grantor's right to the trademarks and trademark registrations listed on Exhibit A attached to the Original Agreement, as supplemented by Exhibit A-1 attached hereto, as the same may be updated hereafter from time to time (Exhibit A attached to the Original Agreement, as supplemented by Exhibit A-1 attached hereto, as the same may be updated hereafter from time to time, is hereinafter referred to as "Exhibit A");

(iv) All of Grantor's right, title, and interest, in and to the patents and patent applications listed on Exhibit B attached to the Original Agreement, as supplemented by Exhibit B-1 attached hereto, as the same may be updated hereafter from time to time (Exhibit B attached to the Original Agreement, as supplemented by Exhibit B-1 attached hereto, as the same may be updated hereafter from time to time, is hereinafter referred to as "Exhibit B");

(v) All of Grantor's right, title and interest to register trademark claims under any state or federal trademark law or regulation of any foreign country and to apply for, renew, and extend the trademark registrations and trademark rights, the right (without obligation) to sue or bring opposition or cancellation proceedings in the name of Grantor or in the name of TBCC for past, present, and future infringements of the trademarks, registrations, or trademark rights and all rights (but not obligations) corresponding thereto in the United States and any foreign country;

(vi) All of Grantor's right, title, and interest in all patentable inventions, and to file applications for patent under federal patent law or regulation of any foreign country, and to request reexamination and/or reissue of the patents, the right (without obligation) to sue or bring interference proceedings in the name of Grantor or in the name of TBCC for past, present, and future infringements of the patents, and all rights (but not obligations) corresponding thereto in the United States and any foreign country;

(vii) the entire goodwill of or associated with the businesses now or hereafter conducted by Grantor connected with and symbolized by any of the aforementioned properties and assets;

(viii) All general intangibles relating to the foregoing and all other intangible intellectual or other similar property of the Grantor of any kind or nature, associated with or arising out of any of the aforementioned properties and assets and not otherwise described above; and

(ix) All products and proceeds of any and all of the foregoing (including, without limitation, license royalties and proceeds of infringement suits) and, to the extent not otherwise included, all payments under insurance, or any indemnity, warranty, or guaranty payable by reason of loss or damage to or otherwise with respect to the Collateral.

"Obligations" means all obligations, liabilities, and indebtedness of Grantor to TBCC, whether direct, indirect, liquidated, or contingent, and whether arising under this Agreement, the Security Agreement, any other of the Loan and Lease Documents, or otherwise, including all costs and expenses described in Section 9.8 hereof.

1.2 Construction. Unless the context of this Agreement clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, and the term "including" is not limiting. The words "hereof," "herein," "hereby," "hereunder," and other similar terms refer to this Agreement as a whole and not to any particular provision of this Agreement. Any initially capitalized terms used but not defined herein shall have the meaning set forth in the Security Agreement. Any reference herein to any of the Loan and Lease Documents includes any and all alterations, amendments, extensions, modifications, renewals, or supplements thereto or thereof, as applicable. Neither this Agreement nor any uncertainty or ambiguity herein shall be construed or resolved against TBCC or Grantor, whether under any rule of construction or otherwise. On the contrary, this Agreement has been reviewed by Grantor, TBCC, and their respective counsel, and shall be construed and interpreted according to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions of TBCC and Grantor. Headings have been set forth herein for convenience only, and shall not be used in the construction of this Agreement.

2. GRANT OF SECURITY INTEREST.

To secure the complete and timely payment and performance of all Obligations, and without limiting any other security interest Grantor has granted to TBCC, Grantor hereby grants, assigns, and conveys to TBCC a security interest in Grantor's entire right, title, and interest in and to the Collateral.

3. REPRESENTATIONS, WARRANTIES AND COVENANTS.

Grantor hereby represents, warrants, and covenants that:

3.1 Trademarks; Patents. A true and complete schedule setting forth all federal and state trademark registrations owned or controlled by Grantor or licensed to Grantor, together with a summary description and full information in respect of the filing or issuance thereof, is set forth on Exhibit A (as defined above). A true and complete schedule setting forth all patents and patent applications owned or controlled by Grantor or licensed to Grantor, together with a summary description and full information in respect of the filing or issuance thereof, is set forth on Exhibit B (as defined above).

3.2 Validity; Enforceability. Each of the patents and trademarks is valid and enforceable, and Grantor is not presently aware of any past, present, or prospective claim by any third party that any of the patents or trademarks are invalid or unenforceable, or that the use of any patents or trademarks violates the rights of any third person, or of any basis for any such claims.

3.3 Title. Grantor is the sole and exclusive owner of the entire and unencumbered right, title, and interest in and to each of the patents, patent applications, trademarks, and trademark registrations, free and clear of any liens, charges, and encumbrances, including pledges, assignments, licenses, shop rights, and covenants by Grantor not to sue third persons.

3.4 Notice. Grantor has used and will continue to use proper statutory notice in connection with its use of each of the patents and trademarks.

3.5 Quality. Grantor has used and will continue to use consistent standards of high quality (which may be consistent with Grantor's past practices) in the manufacture, sale, and delivery of products and services sold or delivered under or in connection with the trademarks, including, to the extent applicable, in the operation and maintenance of its merchandising operations, and will continue to maintain the validity of the trademarks.

3.6 Perfection of Security Interest. Except for the filing of a financing statement with the Secretary of State of California and filings with the United States Patent and Trademark Office necessary to perfect the security interests created hereunder, no authorization, approval, or other action by, and no notice to or filing with, any governmental authority or regulatory body is required either for the grant by Grantor of the security interest hereunder or for the execution, delivery, or performance of this Agreement by Grantor or for the perfection of or the exercise by TBCC of its rights hereunder to the Collateral in the United States.

4. AFTER-ACQUIRED PATENT OR TRADEMARK RIGHTS.

If Grantor shall obtain rights to any new trademarks, any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Agreement shall automatically apply thereto. Grantor shall give prompt notice in writing to TBCC with respect to any such new trademarks or patents, or renewal or extension of any trademark registration. Grantor shall bear any expenses incurred in connection with future patent applications or trademark registrations. Without limiting Grantor's obligation under this Section 4, Grantor authorizes TBCC to modify this Agreement by amending Exhibits A or B to include any such new patent or trademark rights. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Exhibits A or B shall in any way affect, invalidate or detract from TBCC's continuing security interest in all Collateral, whether or not listed on Exhibits A or B.

5. LITIGATION AND PROCEEDINGS.

Grantor shall commence and diligently prosecute in its own name, as the real party in interest, for its own benefit, and its own expense, such suits, administrative proceedings, or other action for infringement or other damages as are in its reasonable business judgment necessary to protect the Collateral. Grantor shall provide to TBCC any information with respect thereto requested by TBCC. TBCC shall provide at Grantor's expense all necessary cooperation in connection with any such suits, proceedings, or action, including, without limitation, joining as a necessary party. Following Grantor's becoming aware thereof, Grantor shall notify TBCC of the institution of, or any adverse determination in, any proceeding in the United States Patent and Trademark Office, or any United States, state, or foreign court regarding Grantor's claim of ownership in any of the patents or trademarks, its right to apply for the same, or its right to keep and maintain such patent or trademark rights.

6. POWER OF ATTORNEY.

Grantor hereby appoints TBCC as Grantor's true and lawful attorney, with full power of substitution, to do any or all of the following, in the name, place and stead of Grantor: (a) file this Agreement (or an abstract hereof) or any other document describing TBCC's interest in the Collateral with the United States Patent and Trademark Office; (b) execute any modification of this Agreement pursuant to Section 4 of this Agreement; (c) take any action and execute any instrument which TBCC may deem necessary or advisable to accomplish the purposes of this Agreement; and (d) following an Event of Default (as defined in the Security Agreement), (i) endorse Grantor's name on all applications, documents, papers and instruments necessary for TBCC to use or maintain the Collateral; (ii) ask, demand, collect, sue for, recover, impound, receive, and give acquittance and receipts for money due or to become due under or in respect of

any of the Collateral; (iii) file any claims or take any action or institute any proceedings that TBCC may deem necessary or desirable for the collection of any of the Collateral or otherwise enforce TBCC's rights with respect to any of the Collateral, and (iv) assign, pledge, convey, or otherwise transfer title in or dispose of the Collateral to any person.

7. RIGHT TO INSPECT.

Grantor grants to TBCC and its employees and agents the right to visit Grantor's plants and facilities which manufacture, inspect, or store products sold under any of the patents or trademarks, and to inspect the products and quality control records relating thereto at reasonable times during regular business hours.

8. SPECIFIC REMEDIES.

Upon the occurrence of any Event of Default (as defined in the Security Agreement), TBCC shall have, in addition to, other rights given by law or in this Agreement, the Security Agreement, or in any other Loan Document, all of the rights and remedies with respect to the Collateral of a secured party under the Code, including the following:

8.1 Notification. TBCC may notify licensees to make royalty payments on license agreements directly to TBCC.

8.2 Sale. TBCC may sell or assign the Collateral and associated goodwill at public or private sale for such amounts, and at such time or times as TBCC deems advisable. Any requirement of reasonable notice of any disposition of the Collateral shall be satisfied if such notice is sent to Grantor five (5) days prior to such disposition. Grantor shall be credited with the net proceeds of such sale only when they are actually received by TBCC, and Grantor shall continue to be liable for any deficiency remaining after the Collateral is sold or collected. If the sale is to be a public sale, TBCC shall also give notice of the time and place by publishing a notice one time at least five (5) days before the date of the sale in a newspaper of general circulation in the county in which the sale is to be held. To the maximum extent permitted by applicable law, TBCC may be the purchaser of any or all of the Collateral and associated goodwill at any public sale and shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any public sale, to use and apply all or any part of the Obligations as a credit on account of the purchase price of any collateral payable by TBCC at such sale.

9. GENERAL PROVISIONS.

9.1 Effectiveness. This Agreement shall be binding and deemed effective when executed by Grantor and TBCC.

9.2 Notices. Except to the extent otherwise provided herein, all notices, demands, and requests that either party is required or elects to give to the other shall be in writing and shall be governed by the notice provisions of the Security Agreement.

9.3 No Waiver. No course of dealing between Grantor and TBCC, nor any failure to exercise nor any delay in exercising, on the part of TBCC, any right, power, or privilege under this Agreement or under the Security Agreement or any other agreement, shall operate as a waiver. No single or partial exercise of any right, power, or privilege under this Agreement or under the Security Agreement or any other agreement by TBCC shall preclude any other or further exercise of such right, power, or privilege or the exercise of any other right, power, or privilege by TBCC.

9.4 Rights Are Cumulative. All of TBCC's rights and remedies with respect to the Collateral whether established by this Agreement, the Security Agreement, or any other documents or agreements, or by law shall be cumulative and may be exercised concurrently or in any order.

9.5 Successors. The benefits and burdens of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties; provided that Grantor may not transfer any of the Collateral or any rights hereunder, without the prior written consent of TBCC, except as specifically permitted hereby.

9.6 Severability. The provisions of this Agreement are severable. If any provision of this Agreement is held invalid or unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect only such provision, or part thereof, in such jurisdiction, and shall not in any manner affect such provision or part thereof in any other jurisdiction, or any other provision of this Agreement in any jurisdiction.

9.7 Entire Agreement. This Agreement is subject to modification only by a writing signed by the parties, except as provided in Section 4 of this Agreement. To the extent that any provision of this Agreement conflicts with any provision of the Security Agreement, the provision giving TBCC greater rights or remedies shall govern, it being understood that the purpose of this Agreement is to add to, and not detract from, the rights granted to TBCC under the Security Agreement. This Agreement, the Security Agreement, and the documents relating thereto comprise the entire agreement of the parties with respect to the matters addressed in this Agreement.

9.8 Fees and Expenses. Grantor shall pay to TBCC on demand all costs and expenses that TBCC pays or incurs in connection with the negotiation, preparation, consummation, administration, enforcement, and termination of this Agreement, including: (a) reasonable attorneys' and paralegals' fees and disbursements of counsel to TBCC; (b) costs and expenses (including reasonable attorneys' and paralegals' fees and disbursements) for any amendment, supplement, waiver, consent, or subsequent closing in connection with this Agreement and the transactions contemplated hereby; (c) costs and expenses of lien and title searches; (d) taxes, fees, and other charges for filing this Agreement at the United States Patent and Trademark Office, or for filing financing statements, and continuations, and other actions to perfect, protect, and continue the security interest created hereunder; (e) sums paid or incurred to pay any amount or take any action required of Grantor under this Agreement that Grantor fails to pay or take; (f) costs and expenses of preserving and protecting the Collateral; and (g) costs and expenses (including reasonable attorneys' and paralegals' fees and disbursements) paid or incurred to enforce the security interest created hereunder, sell or otherwise realize upon the Collateral, and otherwise enforce the provisions of this Agreement, or to defend any claims made or threatened against the TBCC arising out of the transactions contemplated hereby (including preparations for the consultations concerning any such matters). The foregoing shall not be construed to limit any other provisions of this Agreement or the Loan and Lease Documents regarding costs and expenses to be paid by Grantor. The parties agree that reasonable attorneys' and paralegals' fees and costs incurred in enforcing any judgment are recoverable as a separate item in addition to fees and costs incurred in obtaining the judgment and that the recovery of such attorneys' and paralegals' fees and costs is intended to survive any judgment, and is not to be deemed merged into any judgment.

9.9 Indemnity. Grantor shall protect, defend, indemnify, and hold harmless TBCC and TBCC's assigns from all liabilities, losses, and costs (including without limitation reasonable attorneys' fees) incurred or imposed on TBCC relating to the matters in this Agreement.

9.10 Further Assurances. At TBCC's request, Grantor shall execute and deliver to TBCC any further instruments or documentation, and perform any acts, that may be reasonably necessary or appropriate to implement this Agreement, the Security Agreement or any other agreement, and the documents relating thereto, including without limitation any instrument or documentation reasonably necessary or appropriate to create, maintain, perfect, or effectuate TBCC's security interests in the Collateral.

9.11 Release. TBCC shall release its security interest in the Intellectual Property Collateral upon the written request of the Grantor so long as: (a) the Obligations are less than \$2,000,000; (b) as of the last day of the month preceding the date of such request, the Grantor had cash and Cash Equivalents on hand, free and clear of any lien or security interest other than in favor of the Secured Party, in an aggregate amount not less than the product of (i) the number of months remaining under the then latest expiring Lease under the Lease Agreement times (ii) one-twelfth of the decrease in the sum of the Grantor's cash and Cash Equivalents during the twelve-month period ended as of the last day of the month preceding the date of such request; and (c) the Grantor has at all times since the date of this Security Agreement not permitted its EBITDA, cash and Cash Equivalents and revenues for any fiscal month in its fiscal year 2001 or for any fiscal quarter in its fiscal years 2002 and 2003 to be less than 75% of its EBITDA, cash and Cash Equivalents and revenues as projected for such fiscal month or quarter, as the case may be, in its financial projections dated May __, 2001 delivered to the Secured Party on or before the date of this Security Agreement, as certified by the chief financial officer of the Grantor in connection with the delivery of the financial statements by the Grantor under Section 29 of the Master Lease and Loan from time to time.


9.12 Governing Law. THE VALIDITY, INTERPRETATION AND ENFORCEMENT OF THIS AGREEMENT AND ANY DISPUTE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, WHETHER SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE GOVERNED BY THE INTERNAL LAWS AND DECISIONS OF THE STATE OF ILLINOIS. ALL DISPUTES BETWEEN THE GRANTOR AND TBCC, WHETHER SOUNDING IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE RESOLVED ONLY BY STATE AND FEDERAL COURTS LOCATED IN CHICAGO, ILLINOIS, AND THE COURTS TO WHICH AN APPEAL THEREFROM MAY BE TAKEN; PROVIDED, HOWEVER, THAT TBCC SHALL HAVE THE RIGHT, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TO PROCEED AGAINST THE GRANTOR OR ITS PROPERTY IN ANY LOCATION REASONABLY SELECTED BY TBCC IN GOOD FAITH TO ENABLE TBCC TO REALIZE ON SUCH PROPERTY, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF TBCC. THE GRANTOR AGREES THAT IT WILL NOT ASSERT ANY PERMISSIVE COUNTERCLAIMS, SETOFFS OR CROSS-CLAIMS IN ANY PROCEEDING BROUGHT BY TBCC. THE GRANTOR WAIVES ANY OBJECTION THAT IT MAY HAVE TO THE LOCATION OF THE COURT IN WHICH TBCC HAS COMMENCED A PROCEEDING, INCLUDING, WITHOUT LIMITATION, ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON FORUM NON CONVENIENS.

9.13 Waiver of Right to Jury Trial. TBCC AND GRANTOR EACH HEREBY WAIVE THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO: (I) THIS AGREEMENT; OR (II) ANY OTHER PRESENT OR FUTURE INSTRUMENT OR AGREEMENT BETWEEN TBCC AND GRANTOR; OR (III) ANY CONDUCT, ACTS OR OMISSIONS OF TBCC OR GRANTOR OR ANY OF THEIR DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, ATTORNEYS OR ANY OTHER PERSONS AFFILIATED WITH TBCC OR GRANTOR; IN EACH OF THE FOREGOING CASES, WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE.


Signature page to Supplement One to
Intellectual Property Security Agreement.

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first written above.


**TRANSAMERICA BUSINESS CREDIT
CORPORATION**

By 
Title SVP

DENDREON CORPORATION

By 
Title SVP of Finance & CFO

SUPPLEMENTAL LIST OF TRADEMARKS



DENDREON CORPORATION
 MODIFIED TRADEMARK STATUS CHART
 MAY 2001

CONFIDENTIAL

TRADEMARK/COUNTRY	APPLICATION/REGISTRATION NUMBER	CURRENT STATUS
UNITED STATES		
DACS United States	2,188,041	Registered
DENDREON United States	75/283,623	Pending
DENDREON United States	76/165,904	Pending
DENDREON United States	75/282,526	Pending
MYLOVENGE United States	76/028,099	Pending
MYZENIUM United States	75/927,065	Pending
NEUVENGE United States	76/009,430	Pending
NEUZENIUM United States	75/927,050	Pending
PROVENGE United States	75/927,064	Pending
PROZENIUM United States	75/906,694	Pending
CANADA		
MYLOVENGE Canada	1,071,645	Pending
PROVENGE Canada	1,071,470	Pending
EUROPEAN COMMUNITY (CTM)		
MYLOVENGE European Community	1,817,899	Pending
PROVENGE European Community	1,816,974	Pending

SUPPLEMENTAL LIST OF PATENTS

CONFIDENTIAL

Page 1 of 5

05/23/2001

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000328	1000	Methods for Enriching CD34+ Human Hematopoietic Progenitor Cells	7636-0001	08/31/1994	08/299,468	ISS			12/12/1995	08/31/2014	Van Vlasselaer	US	5,474,687
00000330	1001	Separation Apparatus and Method	7636-0001.30	12/11/1995	08/570,397	ISS			09/02/1997	12/11/2015	Van Vlasselaer	US	5,663,051
00000355	1100	Reagent for Cell Separation	7636-0002	04/09/1986	06/649,819	ISS			05/22/1990	05/22/2007	Dom	US	4,927,749
00000359	1200	Cell Separation Process	7636-0003	03/25/1987	07/049,863	ISS			05/22/1990	03/25/2007	Dom	US	4,927,750
00000360	1300	Centrifugation Syringe, System and Method	7636-0004	08/31/1994	08/298,882	ISS			11/28/1996	08/31/2014	Van Vlasselaer	US	5,577,513
00000364	1400	Methods for Enriching Fetal Cells from Maternal Body Fluids	7636-0005	08/31/1994	08/299,468	ISS			07/08/1997	08/31/2014	Van Vlasselaer	US	5,646,004
00000365	1500	Methods for Enriching Specific Cell Types by Density Gradient Centrifugation	7636-0006	08/31/1994	08/299,467	ISS			11/24/1998	08/31/2015	Van Vlasselaer	US	5,840,502
00000366	1600	Methods for Enriching Breast Tumor Cells	7636-0007	08/31/1994	08/299,465	ISS			07/15/1997	08/31/2014	Van Vlasselaer	US	5,648,223
00000367	1700	Potent Antigen Presenting Cell Method and Composition	7636-0008	07/12/1995	08/501,987	ISS			09/19/2000	07/12/2015	van Schooten, Peshwa	US	6,121,044
00000410	1800	Cell Separation Composition (as amended)	7636-0009	12/11/1995	08/570,120	ISS			08/04/1998	12/11/2015	Patelbumpat, Van	US	5,789,148

TRADEMARK

REFL: 002345 FRAME: 0316

05/23/2001

CONFIDENTIAL**CONFIDENTIAL****DENDREON INTELLECTUAL PROPERTY, PATENT REPORT**

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000434	1900	Immunostimulatory Method	7636-0010	12/28/1995	084579,823	ISS			06/27/2000	09/03/2015	Ruegg, Laus, Wu	US	6,080,409
00000435	1901	Immunostimulatory Composition and Method	7636-0010.20	03/21/1997	080823,008	ABA					Ruegg, Laus, Wu	US	
00000436	1902	Immunostimulatory Compositions	7636-0010.21	09/03/1998	081146,283	ISS			11/02/1999	09/03/2015	Ruegg, Laus, Wu	US	5,976,546
00000437	1902.01	Immunostimulatory Composition and Method	7636-0010.22	06/24/1999	093344,195	ISS			04/03/2001	09/03/2015	Ruegg, Laus, Wu	US	6,210,862
00000462	2000	Growth Arrest Gene Compositions and Methods (SG2.120)	7636-0011.30	06/27/1997	08883,070	ISS			12/07/1999	06/27/2017	Ruegg, Engleman, Laus	US	5,998,589
00000486	2100	Cell Washing Device and Method	7636-0012.30	07/17/1998	091110,326	ISS			03/06/2001	07/17/2018	Van Vlasselaer, Hasan	US	6,197,579
00000512	2201	Composition and Method for Inducing an Immune Response Against Tumor-Related Antigens	7636-0013.10	04/10/1998	09402,845	PEN					Laus, Ruegg, Shapero,	US	
00000536	2300	Process for Making Silanized Colloidal Silica	7636-0014	01/14/1998	093006,775	ISS			01/18/2000	01/14/2018	Van Vlasselaer, Hasan	US	6,015,843
00000538	2400	Prostate Tumor Polynucleotide and Antigen Compositions	7636-0015.30	07/09/1998	09112,086	ISS			02/27/2001	07/09/2018	Laus, Shapero, Tsavaler	US	6,194,152
00000554	2500	Method for Preparation and In Vivo Administration of Antigen Presenting Cell Composition	7636-0016.30	06/01/1998	093323,880	PEN					Van Vlasselaer	US	

TRADEMARK

05/23/2001

CONFIDENTIAL**CONFIDENTIAL****DENDREON INTELLECTUAL PROPERTY, PATENT REPORT**

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000567	2600	Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific Monoclonal Antibody	7636-0019	08/28/1998	60/959,292	ABA					Laus, Vidovic	US	
00000568	2601	Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific Monoclonal Antibody	7636-0019.30	08/26/1999	09/363,663	PEN					Laus, Vidovic	US	
00000571	2700	Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation	7636-0020	12/14/1998	60/112,324	ABA					Laus, Vidovic, Haktum	US	
00000572	2700.01	Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation	7636-0020.30	12/14/1999	09/461,684	PEN					Laus, Vidovic, Haktum	US	
00000575	2800	Suppressor and Progenitor Cells	7636-0013.33	11/04/1992	07/971,723	ISS			11/16/1999	11/16/2016	Strober	US	5,985,656
00000576	2801	Suppressor and Progenitor Cells	7636-0065.33	11/16/1998	09/442,171	PEN					Strober	US	
00001010	2900	Suppressor and Progenitor Cells	7636-014	08/17/1992	07/631,210 CIP	ABA					Strober	US	
00000597	3000	Methods for In-Vivo T Cell Activation By Antigen-Pulsed Dendritic Cells	7636-0030.30	12/20/1995	08/575,432	PEN					Engleman, et al	US	
00000621	3100	Methods for Using Dendritic Cells to Activate T Cells	7636-0041.30	09/06/1994	08/301,157	PEN					Engleman, et al	US	

TRADEMARK

-----REEL: 002345 FRAME: 0318

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000622	3200	Methods for In-Vivo T Cell Activation By Antigen-Pulsed Dendritic Cells	7636-0057.32	12/29/1995	08/575,432	PEN					Engleman, et al	US	
00000625	3300	Methods for Using Dendritic Cells to Activate Gamma/Delta T Cell Receptor Positive T Cells	7636-0022.999	12/01/1993	08/160,571	ABA					Engleman, et al	US	
00000626	3301	Methods for Using Dendritic Cells to Activate Gamma/Delta T Cell Receptor Positive T Cells	7636-0060.30	02/28/1996	08/610,195	PEN					Engleman, et al	US	
00000627	3400	Isotype Vaccination Against B Cell Lymphoma	7636-0064.30	03/14/1990	07/463,511	PEN					Bohlen, et al	US	
00000649	3500	A Dendritic Cell Isolated from Human Peripheral Blood Mononuclear Cells	7636-0017	10/08/1999	7	ABA					Monji, Peshwa	US	
00001009	3501	A Dendritic Cell Isolated from Human Peripheral Blood Mononuclear Cells	7636-0017.30	10/08/2000	09/684,308	PEN					Monji, Peshwa	US	
00000650	4000	Cryopreservation of Antigen-loaded Dendritic Cells and Their Precursors in Serum-Free Media	7636-0021	12/03/1999	60/168,991	ABA					Monji, Peshwa	US	
00001664	4001	Cryopreservation of Antigen-loaded Dendritic Cells and Their Precursors in Serum-Free Media	7636-0021.30	01/12/2000	09/728,424	PEN					Monji, Peshwa	US	
00000651	4100	Compositions and Methods for Dendritic Cell-Based Immunotherapy	7636-0022	03/30/2000	60/193,504	ABA					Laus, Vidovic, Graddis	US	
00001707	4100.01	Compositions and Methods for Dendritic Cell-Based Immunotherapy	7636-0022.30	03/30/2001	7	PEN					Laus, Vidovic, Graddis	US	

TRADEMARK

05/23/2001

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number

TRADEMARK

REEL: 002345 FRAME: 0320

CONFIDENTIAL

**DENDREON CORPORATION
MODIFIED TRADEMARK STATUS CHART
MAY 2001**

TRADEMARK/COUNTRY	APPLICATION/REGISTRATION NUMBER	CURRENT STATUS
UNITED STATES		
DACS United States	2,188,041	Registered
DENDREON United States	75/283,623	Pending
DENDREON United States	76/165,904	Pending
DENDREON United States	75/282,526	Pending
MYLOVENGE United States	76/028,099	Pending
MYEZENIUM United States	75/927,065	Pending
NEUVENGE United States	76/009,430	Pending
NEUZENIUM United States	75/927,050	Pending
PROVENGE United States	75/927,064	Pending
PROZENIUM United States	75/906,694	Pending
CANADA		
MYLOVENGE Canada	1,071,645	Pending
PROVENGE Canada	1,071,470	Pending
EUROPEAN COMMUNITY (CTM)		
MYLOVENGE European Community	1,817,899	Pending
PROVENGE European Community	1,816,974	Pending

CONFIDENTIAL

CONFIDENTIAL

Page 1 of 5

05/23/2001

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000329	1000	Methods for Enriching CD34+ Human Hematopoietic Progenitor Cells	7636-0001	08/31/1994	08/299,469	ISS			12/12/1995	08/31/2014	Van Vlasselaer	US	5,474,687
00000330	1001	Separation Apparatus and Method	7636-0001.30	12/11/1995	08/570,397	ISS			09/02/1997	12/11/2015	Van Vlasselaer	US	5,663,051
00000355	1100	Reagent for Cell Separation	7636-0002	04/09/1986	06/849,819	ISS			05/22/1990	05/22/2007	Dom	US	4,927,749
00000359	1200	Cell Separation Process	7636-0003	03/25/1987	07/049,863	ISS			05/22/1990	03/25/2007	Dom	US	4,927,750
00000360	1300	Centrifugation Syringe, System and Method	7636-0004	08/31/1994	08/298,882	ISS			11/26/1996	08/31/2014	Van Vlasselaer	US	5,577,513
00000384	1400	Methods for Enriching Fetal Cells from Maternal Body Fluids	7636-0005	08/31/1994	08/299,468	ISS			07/08/1997	08/31/2014	Van Vlasselaer	US	5,646,004
00000385	1500	Methods for Enriching Specific Cell Types by Density Gradient Centrifugation	7636-0006	08/31/1994	08/299,467	ISS			11/24/1998	08/31/2015	Van Vlasselaer	US	5,840,502
00000386	1600	Methods for Enriching Breast Tumor Cells	7636-0007	08/31/1994	08/299,465	ISS			07/15/1997	08/31/2014	Van Vlasselaer	US	5,648,223
00000387	1700	Potent Antigen Presenting Cell Method and Composition	7636-0008	07/12/1995	08/501,987	ISS			08/19/2000	07/12/2015	van Schooten, Peshwa	US	6,121,044
00000410	1800	Cell Separation Composition (as amended)	7636-0009	12/11/1995	08/570,120	ISS			08/04/1996	12/11/2015	Paethumpat, Van	US	5,789,148

TRADEMARK

REEL: 002345 FRAME: 0322

05/23/2001

CONFIDENTIAL

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000434	1900	Immunostimulatory Method	7636-0010	12/28/1995	08579,823	ISS			06/27/2000	09/03/2015	Ruegg, Laus, Wu	US	6,080,409
00000435	1901	Immunostimulatory Composition and Method	7636-0010.20	03/21/1997	081823,008	ABA					Ruegg, Laus, Wu	US	
00000436	1902	Immunostimulatory Compositions	7636-0010.21	09/03/1998	09146,283	ISS			11/02/1999	09/03/2015	Ruegg, Laus, Wu	US	5,976,546
00000437	1902.01	Immunostimulatory Composition and Method	7636-0010.22	06/24/1999	091344,195	ISS			04/03/2001	09/03/2015	Ruegg, Laus, Wu	US	6,210,862
00000462	2000	Growth Arrest Gene Compositions and Methods (S92-120)	7636-0011.30	06/27/1997	080883,070	ISS			12/07/1999	06/27/2017	Ruegg, Engelman, Laus	US	5,998,599
00000465	2100	Cell-Washing Device and Method	7636-0012.30	07/17/1998	091148,326	ISS			03/06/2001	07/17/2018	Van Vlasselaer, Hasan	US	6,197,579
00000512	2201	Composition and Method for Inducing an Immune Response Against Tumor-Related Antigens	7636-0013.10	04/10/1998	091402,845	PEN					Laus, Ruegg, Shapero,	US	
00000536	2300	Process for Making Silanized Colloidal Silica	7636-0014	01/14/1998	091006,775	ISS			01/18/2000	01/14/2018	Van Vlasselaer, Hasan	US	6,015,843
00000538	2400	Prostate Tumor Polynucleotide and Antigen Compositions	7636-0015.30	07/08/1998	09112,086	ISS			02/27/2001	07/09/2018	Laus, Shapero, Tsavaler	US	6,194,152
00000564	2500	Method for Preparation and In Vivo Administration of Antigen Presenting Cell Composition	7636-0016.30	06/01/1998	09323,860	PEN					Van Vlasselaer	US	

05/23/2001

CONFIDENTIAL**CONFIDENTIAL****DENDREON INTELLECTUAL PROPERTY, PATENT REPORT**

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000567	2600	Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific Monoclonal Antibody	7636-0019.30	08/28/1998	60098,292	ABA					Laus, Vidovic	US	
00000568	2601	Selective Apoptosis of Neoplastic Cells by an HLA-DR Specific Monoclonal Antibody	7636-0019.30	08/28/1999	08/363,663	PEN					Laus, Vidovic	US	
00000571	2700	Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation	7636-0020	12/14/1998	60112,324	ABA					Laus, Vidovic, Hakim	US	
00000572	2700.01	Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation	7636-0020.30	12/14/1999	08/461,684	PEN					Laus, Vidovic, Hakim	US	
00000575	2800	Suppressor and Progenitor Cells	7636-0013.33	11/04/1992	07/971,723	ISS			11/16/1999	11/16/2016	Strober	US	5,985,656
00000576	2801	Suppressor and Progenitor Cells	7636-0065.33	11/16/1999	09/442,171	PEN					Strober	US	
00001010	2900	Suppressor and Progenitor Cells	7636-014	08/17/1992	07/931,210 CP	ABA					Strober	US	
00000597	3000	Methods for In-Vivo T Cell Activation By Antigen-Pulsed Dendritic Cells	7636-0030.30	12/20/1995	08/575,432	PEN					Engleman, et al	US	
00000621	3100	Methods for Using Dendritic Cells to Activate T Cells	7636-0041.30	09/06/1994	08/301,157	PEN					Engleman, et al	US	

TRADEMARK

REEL: 002345 FRAME: 0324

CONFIDENTIAL

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number
00000622	3200	Methods for In-Vivo T Cell Activation By Antigen-Pulsed Dendritic Cells	7636-0057.32	12/20/1995	08/575,432	PEN					Engleman, et al	US	
00000625	3300	Methods for Using Dendritic Cells to Activate Gamma/Delta T Cell Receptor Positive T Cells	7636-022-999	12/01/1993	08/160,571	ABA					Engleman, et al	US	
00000626	3301	Methods for Using Dendritic Cells to Activate Gamma/Delta T Cell Receptor Positive T Cells	7636-0060.30	02/28/1996	08/610,195	PEN					Engleman, et al	US	
00000627	3400	Idiotypic Vaccination Against B Cell Lymphoma	7636-0064.30	03/14/1990	07/493,511	PEN					Bohlen, et al	US	
00000649	3500	A Dendritic Cell Isolated from Human Peripheral Blood Mononuclear Cells	7636-0017	10/08/1999		ABA					Monji, Peshwa	US	
00001009	3501	A Dendritic Cell Isolated from Human Peripheral blood Mononuclear Cells	7636-0017.30	10/08/2000	09/684/308	PEN					Monji, Peshwa	US	
00000650	4000	Cryopreservation of Antigen-loaded Dendritic Cells and Their Precursors in Serum-Free Media	7636-0021	12/03/1999	60/168,991	ABA					Monji, Peshwa	US	
00001664	4001	Cryopreservation of Antigen-loaded Dendritic Cells and Their Precursors in Serum-Free Media	7636-0021.30	01/12/2000	09/728,424	PEN					Monji, Peshwa	US	
00000651	4100	Compositions and Methods for Dendritic Cell-Based Immunotherapy	7636-0022	03/30/2000	60/193,504	ABA					Laus, Vidovic, Graddis	US	
00001707	4100.01	Compositions and Methods for Dendritic Cell-Based Immunotherapy	7636-0022.30	03/30/2001		PEN					Laus, Vidovic, Graddis	US	

TRADEMARK

05/23/2001

CONFIDENTIAL

CONFIDENTIAL

DENDREON INTELLECTUAL PROPERTY, PATENT REPORT

Barcode	Dendreon Number	Title	Docket Number	Filing Date	Application Number	Status	Published Date	Published Number	Issued Or Grant Date	Expiry Date	Inventor	Country	Patent Number



RECEIPT

Conveying Party: Dendreon Corporation

Receiving Party: Transamerica Business Credit Corporation

Type of document: Security Agreement

Date filed: August 7, 2001

Filing fee: \$265

Number of trademarks involved: 10